Structure Therapeutics (GPCR) moved into focus after publishing detailed Phase 2b ACCESS data for its oral GLP-1 candidate aleniglipron in Nature Medicine, alongside presentations at the American Diabetes Association’s 86th Scientific Sessions.

Despite the positive ACCESS data and a busy conference schedule in recent weeks, Structure Therapeutics' share price has come under pressure. The 90 day share price return is down 33.49% and the year to date share price return is down 44.83%, even as the 1 year total shareholder return is 77.85%, hinting at earlier enthusiasm giving way to a cooling of momentum.

If this kind of obesity and diabetes pipeline news has your attention, it can be useful to widen your watchlist to other healthcare AI driven opportunities using the 39 healthcare AI stocks.

So, with GPCR trading at a market cap of about US$2.7b, recent returns cooling and analysts’ price targets far above the last close, is this a reset that opens an entry point, or is future growth already baked in?

Preferred Price to Book Multiple of 1.8x: Is it justified?

On a simple yardstick like price to book, Structure Therapeutics trades at 1.8x, which sits below both the US Pharmaceuticals industry average and its peer group.

The P/B ratio compares the stock price with the accounting value of net assets on the balance sheet. It is often used for early stage or loss making biopharma businesses where earnings are not yet a useful guide. For a clinical stage company with no meaningful revenue and an annual net loss of $141.2m, book value can act as a rough proxy for the capital backing the pipeline.

Here, the 1.8x P/B multiple looks restrained when set against the US Pharmaceuticals industry at 2.2x and a peer group closer to 5.8x. That gap suggests the market is assigning a lower premium to GPCR’s asset base and pipeline versus many comparables, even though analysts still see substantial upside in their collective price target relative to the last close of $37.58.

Result: Price to book of 1.8x (UNDERVALUED)

However, investors still have to weigh clinical and regulatory uncertainty around its pipeline, alongside continued annual net losses of US$141.2m, with no current revenue base.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Given the mixed mood in the recent share price and valuation signals, it makes sense to move fast, review the underlying data, and pressure test the story against the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If this kind of focused research helps sharpen your thinking on GPCR, do not stop here. Use curated stock lists to keep uncovering fresh opportunities.

• Hunt for potential mispriced opportunities by scanning the 49 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Strengthen the income side of your portfolio by checking out the 9 dividend fortresses built around higher yield and resilience.
• Prioritise balance sheet strength by reviewing the solid balance sheet and fundamentals stocks screener (46 results) to spot companies with financial foundations that can support long term plans.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.